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Abstract
Background: Solid tumors, including head and neck squamous cell carcinomas (HNSCC), arise as a result of genetic and
epigenetic alterations in a sustained stress environment. Little work has been done that simultaneously examines the
spectrum of both types of changes in human tumors on a genome-wide scale and results so far have been limited and
mixed. Since it has been hypothesized that epigenetic alterations may act by providing the second carcinogenic hit in gene
silencing, we sought to identify genome-wide DNA copy number alterations and CpG dinucleotide methylation events and
examine the global/local relationships between these types of alterations in HNSCC.
Methodology/Principal Findings: We have extended a prior analysis of 1,413 cancer-associated loci for epigenetic changes
in HNSCC by integrating DNA copy number alterations, measured at 500,000 polymorphic loci, in a case series of 19 primary
HNSCC tumors. We have previously demonstrated that local copy number does not bias methylation measurements in this
array platform. Importantly, we found that the global pattern of copy number alterations in these tumors was significantly
associated with tumor methylation profiles (p,0.002). However at the local level, gene promoter regions did not exhibit a
correlation between copy number and methylation (lowest q=0.3), and the spectrum of genes affected by each type of
alteration was unique.
Conclusion/Significance: This work, using a novel and robust statistical approach demonstrates that, although a ‘‘second
hit’’ mechanism is not likely the predominant mode of action for epigenetic dysregulation in cancer, the patterns of
methylation events are associated with the patterns of allele loss. Our work further highlights the utility of integrative
genomics approaches in exploring the driving somatic alterations in solid tumors.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the eighth
most commonly diagnosed malignancy in males, responsible for
over an estimated 11,000 deaths each year in the United States
[1]. The genetic alterations common to HNSCCs have been
characterized using both cytogenetic and molecular approaches:
Importantly, the presence of genetic imbalances, specifically loss in
chromosomal regions 3p, 8p, 9p, 15p, 18q, 22q and gains in 1q,
3q, 8q, 11q, 14q, 16q, 20q have been shown to be significantly
associated with poor patient survival [2,3,4,5,6]. Epigenetic
alterations commonly observed in this disease include promoter
hypermethylation, resulting in gene silencing, of CDKN2A, CDH1,
DAPK1, RASSF1, and MGMT, which have been shown to be
associated with patient outcome [7,8,9]. Evidence has emerged
that CDKN2A [10,11], RASSF1 [12], and other genes are regulated
both by hypermethylation and allele loss in many solid tumor types
[13,14,15] leading to the hypothesis that, in addition to classical
Knudson inactivation of tumor suppressors through mutation
[16], first and second hits commonly occur in the form of
promoter methylation and loss of heterozygosity (LOH) even in
the absence of mutation.
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fundamental in the genesis of neoplasia, resulting in the
inappropriate activity level of cell signaling pathways that regulate
key processes such as cellular growth and differentiation, DNA
fidelity, apoptosis, and metabolic stability. Thus, a more complete
study of carcinogenesis would include simultaneous evaluation of
multiple types of alterations in common tumors. Investigation of
various cancers using genome level technologies, such as high-
resolution single nucleotide polymorphism (SNP) microarrays to
measure somatically arising allelic imbalance, have shown that
these genetic alterations profiles are remarkably diverse [3,17,18].
Further, recent large scale array-based studies of epigenetic events
have yielded similar insight into the pattern of gene silencing in
cancers, in that alterations to promoter methylation status of genes
occurs in a highly variable pattern even amongst tumors arising
from the same tissue or cell type [19,20,21]. Results from studies
employing these methods have been effective in gaining insight
into the basis of hereditary disease [22] and in identifying novel
candidate cancer genes [23].
Our technological capability to assess both genetic and
epigenetic genome-wide alterations has improved. Thus, it is
now critically important to begin integrated analyses that will
allow us to define the relationship between epigenetic alterations
(represented by changes in DNA methylation) and genetic changes
(represented by alterations in copy number) that comprise the
etiologic keystones of malignant disease. The need for combined
high-resolution profiling of DNA copy number and methylation
profiling is becoming recognized, particularly as pharmacologic
targeting of the epigenome has gained momentum, and methods
to simultaneously investigate both types of alterations are emerging
[24,25,26]. In addition, recent investigations in gliomas [21] and
cancer cell lines [27,28] using combinatorial high-throughput
methods have elucidated individual genes that are differentially
regulated through these mechanisms; however, the global
relationships between epigenetic and copy number profiles in
human tumors remain poorly characterized.
We hypothesized that epigenetic and genetic alterations in
HNSCC are clonally selected in a fashion that is not independent.
To investigate this, we have integrated these genomic-level data in
an analysis of 19 primary HNSCCs.
Results
DNA Copy Number and Methylation Measurement
Somatic DNA copy number analysis was performed on a
representative case-series of 19 malignant HNSCCs (Table 1) with
high-density Affymetrix 500 k SNP mapping arrays, using
matched blood DNA as referents. For the purpose of exploration,
copy number data were subjected to unsupervised hierarchical
clustering (Ward’s method with Hamming distance) and coordi-
nately arranged by chromosome (Figure 1A). Consistent with the
considerable literature addressing the cytogenetics of HNSCC
[29,30], frequent gross structural abnormalities of chromosomes
8q or 3q are observed in 6 (32%) of the cases, appearing as
amplifications (red) or allele losses (green), while smaller-scale
aberrations are identifiable in most samples.
Previously, we reported the methylation status of 1505 CpG loci
using the Illumina GoldenGate platform in 68 HNSCC tumors
(including the 19 samples with copy number data) [20]. Employing
an unsupervised method for clustering methylation data using a
mixture of beta distributions, termed recursively partitioned
mixture modeling (RPMM) [31], we showed that normal
epithelium is distinguished from tumor in the classifications
(epigenetic signatures) that result. When restricting to tumor-only
modeling, six methylation profile classes were defined, and class
membership was significantly associated with tumor stage
(p,0.01), patient age (p,0.01), and marginally associated with
tumor site (p,0.10) and Human Papillomavirus (HPV) status
(p,0.10) by permutation tests [20]. Tumor membership in Class 5
carried an increased risk of high stage disease while Classes 6 and 2
were associated with a protective effect against advanced stage.
Patients in Class 4 had a higher prevalence of HPV16 positivity
and Class 3 had the highest proportion of laryngeal tumors. These
associations lend biological significance to the six epigenetic
profiles that were identified. Subsequent analyses presented in this
report utilize these previously published methylation classifica-
tions. Loci profiled for methylation (hypermethylated=blue,
hypomethylated=yellow) for the 19 tumors with copy number
measurements were visualized by clustering (Figure 1B) and are
ordered by their corresponding placement within a dendrogram
obtained by RPMM grouping, with the terminal nodes filled by
Ward’s method of hierarchical clustering. RPMM classes are
indicated beneath the dendrogram.
Local Molecular Alterations Are Not Correlated
To compare methylation levels and copy number alteration
(CNA) in greater detail, we generated integrated color image plots
of methylation and copy number profiles for individual genomic
regions around specific loci (Figure 2C) and entire chromosomes of
interest (Figure 2A/B and Figure S1), where samples were grouped
by RPMM methylation class membership. These plots illustrate
the local relationships between DNA methylation and CNA.
Specifically, certain loci (e.g. SOX17, chromosome 8) in tumors
with allelic amplification exhibit hypermethylation in nearby
CpGs compared to those tumors without allelic imbalance in that
Table 1. Clinicopathologic characteristics of HNSCC study
participants.
All Cases
(n=68)
Cases For Methylation
and Copy Number Analysis
(n=19)
Gender, n (%)
Female 14 (21) 4 (21)
Male 54 (79) 15 (79)
Age at Diagnosis
Range 25–85 25–85
Mean (SD) 58 (11.4) 59 (15.1)
HPV16 Status, n (%)
Positive 10 (15) 3 (16)
Negative 56 (82) 16 (84)
Tumor Site, n (%)
Oral 35 (52) 15 (79)
Pharynx 26 (38) 2 (10.5)
Larynx 7 (10) 2 (10.5)
Clinical Stage, n (%)
I 5 (7) 2 (10.5)
II 9 (13) 2 (10.5)
III 9 (13) 5 (26)
IV 26 (38) 9 (47)
Unknown 19 (28) 1 (5)
doi:10.1371/journal.pone.0009651.t001
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PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9651region. At the same time, methylation values were stable for most
loci across all the samples despite local regions of gain or loss,
demonstrating that, as we have previously reported [32], the
relationship between methylation profile and CNA is neither an
artifact of the analysis nor allelic bias in the samples.
Initial analyses sought to take advantage of ‘‘two hit’’ gene
inactivation, as proposed by Knudson [16], in order to identify
potential novel loci as candidates that are causal in this disease. We
scanned the genome for locations where there was a systematic
relationship between copy number and methylation, such as
previously reported sites of hypermethylation and LOH. Calcu-
lating the Pearson correlations for all overlapping loci, we
encountered only eight loci (q,0.05) that demonstrated a
significant correlation between these disparate mechanisms of
gene silencing. This apparent independence was true both at
individual loci and when averaged over multiple CpGs upstream
of the transcriptional start site (TSS) (Table 2). For example,
hypermethylation and LOH occurred infrequently within the
CDKN2A gene and only at one CpG, while more often DNA
methylation occurred in the absence of aberrant copy number
states or vice-versa (Figure 2C). Importantly, many other loci (such
as those within MGMT) had little variation in either form of
molecular alteration.
We next investigated each form of alteration individually, and
estimated the deviations from their expected normal values to
determine the significance of CNA and DNA methylation
alterations in HNSCC. Volcano plots of gene-specific mean
methylation alteration and mean copy number alteration versus p-
value revealed distinctions in promoter-associated alterations
between molecular processes, evident through an increased
tendency for significant loss of methylation versus a tendency for
significant increase in copy number (Figure 3A and Table S1). To
further explore allele losses in the context of the overall process of
methylation at the specific loci on the array, these data were
stratified by their RPMM methylation classification. Specifically,
‘‘left class’’ included tumors in RPMM Methylation Classes 1–4,
while ‘‘right class’’ included Methylation Classes 5–6. These
groupings represent the two main epigenetically distinct methyl-
ation class subsets and are defined as the initial left and right splits
of the RPMM clustering dendrogram, shown in Figure 1B, as
adapted from [20]. Interestingly, the pattern of allelic copy
number and methylation alterations differed considerably between
right and left classes (Figure 3B), with significantly decreased levels
of methylation alterations and significantly increased CNA
occurring primarily in the left class. This provides evidence that
different global processes are at work between the groups of
methylation classes and that this distinction is replicated in the
copy number data.
CNA and Methylation Profiles Are Not Independent
In order to more fully explore the evidence of a global
epigenetic effect on copy number, we plotted genome-wide allele
copy number changes in tumors stratified by RPMM methylation
class membership (Figure 4). The extent of copy number
alterations varied significantly by methylation class (permutation
test p,0.002), with tumors in Methylation Classes 1 and 3 showing
substantial, large-scale copy number alteration relative to other
tumors. This clearly shows that copy number and methylation
alterations do not occur independently. If there were no
association between genetic and epigenetic alterations, one would
observe an even distribution of aberrant copy number states across
methylation classes. To investigate the notion that clinical
variables previously shown to be associated with the methylation
classes may also be the reason for similar copy number data
clustering, tests for association between the degree of CNA and the
clinical covariates age, site, stage, and HPV16 status were
performed. Importantly, these tests were not statistically signifi-
cant, further indicating that a relationship between theses global
Figure 1. Hierarchical clustering heatmaps for 19 HNSCC tumors. A) DNA copy number states are arranged by chromosome for 500,000 SNP
loci. Copy number is red for amplified regions up to 4+ copies, white for 2 normal copies, and green for allele loss to 0 copies. Tumors are ordered by
unsupervised hierarchical clustering and are dichotomized into low/high CNA clusters. B) Methylation loci (more methylated=blue, less
methylated=yellow) are grouped by Euclidean distance and tumors samples are ordered first by RPMM class structure (green branches) then by
simple hierarchical clustering (black branches). Tumor IDs are provided below each plot and ‘‘high CNA’’ samples are colored orange for reference.
doi:10.1371/journal.pone.0009651.g001
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clinical parameters in both datasets.
Global Methylation in High/Low CNA Tumors
Since it has long been hypothesized that genomic instability is
related to decreased levels of global DNA methylation, we
measured LINE-1 methylation, as a surrogate marker of global
methylation, in tumors with available DNA (n=11). The tumors
that hierarchically clustered in the high CNA group (see Figure 1A)
had generally lower LINE-1 methylation than tumors with low
levels of allelic imbalance (mean differential methylation: 213.2%,
95% CI: (233.6%–7.2%)).
Discussion
We recently constructed epigenetic profiles of HNSCC,
reporting that DNA methylation events are common and
associated with etiologically important exposures [20]. Aberrant
DNA methylation events have been hypothesized to accumulate
initially in a stochastic fashion and, through positive selection,
result in clones that have a growth advantage that leads to the
genesis of a rapidly-dividing tumor. Here we expand upon these
data and include an analysis of chromosomal integrity in these
same tumors. Using genomic-level measurements, we observed a
highly significant association between copy number and DNA
methylation profiles, definitively showing that these modes of gene
regulation are linked in HNSCC. These observations supplement
recent evidence from Sadikovic et al. that copy number alterations
are generally correlated with both methylation and gene
expression levels in osteosarcomas [33]. At the same time, while
specific targeting of genes through both mechanisms occurs in a
deterministic manner within subgroups of patients, when we tested
for regionally matching local (gene level) epigenetic and copy
number events we only observed that global, rather than local,
Figure 2. Integration of copy number and methylation values for 19 HNSCCs. Tumor profiles in combined color image plots for A)
chromosome 8 and B) chromosome 3 are grouped by RPMM-modeled methylation classes. Methylation values (more methylated=blue, less
methylated=yellow) are located to the right, while copy number (red=gain, green=loss) is displayed on the left within each panel. SNP loci are
matched to the nearest CpG locus and these matched loci (common to both subpanels) are oriented coordinately along the chromosomes. For
legibility, the loci are grouped by gene. Note: Chromosome diagrams are not to scale, but centromeric regions are correctly located between genes.
C) Gene-focused copy number and methylation data. The x-axis displays the genomic coordinate (x10
26) for each locus. Vertical yellow lines mark the
TSS and dashed blue lines denote locations of the mapped CpG loci, whose values are displayed on the right portions of the plot for each gene.
Methylation average b is bright blue for fully methylated and bright yellow for unmethylated. Copy number is displayed on the left plot and SNP loci
marked red represent amplified alleles and green for deleted allele calls.
doi:10.1371/journal.pone.0009651.g002
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gene inactivation (LOH followed by epigenetic silencing) is not the
dominant character of somatic alteration over the genome. As the
GoldenGate methylation array investigates nearly 800 cancer-
involving genes and is enriched for tumor suppressor-associated
loci, we were uniquely positioned to investigate just this question.
Recent evidence supports our conclusion, as gene regulation by
CNA and DNA methylation measured at 691 loci in meningiomas
appears to be somewhat mutually exclusive [34]. In addition, our
combined analysis of the promoter regions of previously reported
genes with allele loss or hypermethylation demonstrates that this
situation is rare (see Table S2), however a much larger
investigation with higher resolution is needed to determine if
these alterations occur systematically.
One possible explanation for the association between global
profiles of DNA methylation and copy number is that amplifica-
tion or loss of genetic material may result in a bias of measured
methylation for CpGs within that region, potentially contributing
to the inferred methylation profile (e.g. in our RPMM approach).
Indeed, previous microarray-based methods to determine meth-
ylation status have been hindered by copy number changes that
bias the measured relative methylation values at CpG loci [35].
However, our recent work utilizing bead-arrays has shown that
CNA produces little bias in absolute methylation data generated
on the GoldenGate methylation panel, except in the case of
homozygous deletion [32]. We and others have previously
demonstrated the validity of Illumina GoldenGate methylation
array results with other high- and low-throughput technologies
[36,37].
Integrative analysis revealed that several tumors with similar
methylation profiles had large regions of chromosomal abnormal-
ity, particularly in chromosomes 8 and 3, consistent with the
possible formation of isochromosomes i(8q) and i(3q) in aneuploid
cells. These cytogenetic abnormalities commonly appear in
HNSCC, possibly a result of chromosomal missegregation events
during mitosis [29]. We also observed that Methylation Class 3
tumor data reflect gross allelic amplification of 8q, which extends
through the centromere and partially into 8p, possibly indicating a
distinct mechanism of formation for this anomaly. Among tumors
with an amplified 8q arm, several methylated CpG loci were
observed in this region relative to tumors without this gross
chromosomal alteration. Two mechanisms can be posited to
explain this result. Firstly, epigenetic dysregulation may occur
early in the genesis of these head and neck tumors and aberrant
methylation marks are faithfully replicated despite the amplifica-
tion event, which is consistent with previous reports implicating
epigenetic modification as an early event in the progression of this
disease [reviewed in 38]. In fact, there is evidence that aberrant
methylation in certain chromosomal regions, especially located
near centromeres, predisposes the surrounding area to genetic
alteration, including fragile breakpoint sites [39,40]. On the other
hand, it is possible that this differential methylation occurs
following the chromosomal aberration, possibly in response to
the genetic event and selective pressures. However, we are unable
to distinguish between these possibilities in our data, highlighting
the need for mechanistic studies.
Gain of 8q has been reported as a relatively common event in
HNSCC, particularly at 8q24 [41], which houses the MYC
oncogene, and 8q22, thought to be targeting LRP12 [42].
Similarly, in one-third of our cases we observed amplification of
this entire arm, while putative tumor suppressor genes, such as
SOX17 and PENK, within this amplified chromosomal arm are
methylated. These findings are suggestive of a context wherein
genetic modification (possibly a result of genomic instability) is
responsible for perpetuating inappropriate oncogene expression
with concomitant epigenetic silencing of local tumor suppressors
(Figure 2A).
Molecular alterations in chromosome 3 have been previously
reported as the most prevalent and potentially most important in
HNSCC [43]. Consistent with these findings, we observed
extensive copy number and methylation alterations in this
chromosome. For example, the gastric cancer-associated tumor-
suppressor HRASLS in the amplified q-arms were more highly
methylated than those tumors which possessed normal 3q. In
addition, the proto-oncogenic MST1R loci, associated with poor
prognosis through potentiation of cell scattering and invasion in
breast cancer [44], were unmethylated in most tumors irrespective
of chromosome 3p loss. However, we observed a number of genes
that did not follow the expected directions of methylation within
copy number variable loci, indicating that they may be hitchhikers
or simply regulated by other genetic or epigenetic means. Overall,
these structural modifications in chromosomes 3 and 8 are
consistent with the literature and are thought to develop early
during the genesis of disease [30,45].
Although 13 of the tumors examined (Methylation Classes 1, 3,
and 6, Fig. 4) demonstrated a preponderance of CNA, we
observed a notable lack of CNA among the remaining tumors. We
hypothesize that this may be due to these samples having higher
levels of aberrant epigenetic or non-copy number altering genetic
events such as mutation or chromosomal rearrangements. It is also
possible that clinical stage could account for the observed levels of
abnormal copy number, as this has been reported in other cancers
[46]. Other possible confounders include HPV16 status and tumor
site, although our data do not indicate associations between any of
these covariates and CNA. Larger future studies are required to
investigate the nature of these notable differences with statistical
rigor.
There was also an apparent relationship between global
hypomethylation, represented by the extent of LINE-1 DNA
sequence methylation, and the increased levels of allelic imbalance
Table 2. Methylation and CNA-correlated regions.
Estimate
* p-value q-value
Locus
GRB10_P260_F 0.96 ,1.0E-04 0.01
GRB10_E85_R 0.94 ,1.0E-04 0.01
IHH_P529_F 0.99 ,1.0E-04 0.01
HOXA11_P92_R 0.94 1.0E-04 0.02
DDR2_E331_F 20.91 2.0E-04 0.03
TERT_E20_F 0.85 2.0E-04 0.03
FZD9_P15_R 0.85 4.0E-04 0.03
WNT1_P79_R 0.86 4.0E-04 0.03
PI3_P274_R 20.82 5.0E-04 0.05
IHH_P246_R 0.82 7.0E-04 0.05
Gene Promoter
HOXA11 0.94 1.0E-04 0.04
NID1 20.75 1.4E-03 0.12
GRB10 0.73 1.8E-03 0.12
TIMP3 20.75 2.0E-03 0.12
AFP 20.71 2.2E-03 0.12
*Point estimates represent Pearson product-moment correlation coefficients.
doi:10.1371/journal.pone.0009651.t002
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[47,48] and with the hypothesis that global hypomethylation of
transposable elements culminates in genomic instability. While it is
apparent that the various modes of alteration are related, the
timing of these events is less clear. Our data underscore the need
for additional investigations into the chronology of multifaceted
somatic alterations leading to the onset and progression of this
deadly disease.
In our analysis to define the local relationships between copy
number and methylation, we observed only one gene (where
promoter-associated CpG alterations were averaged), HOXA11,
with a marginally significant correlation between methylation and
copy number alteration, although a number of individual CpG
loci reached significance, including sites within potentially
oncogenic GRB10, IHH, and HOXA11. While the strong positive
correlation at these sites could indicate selection pressure for dual
mechanism inactivation was occurring to promote neoplasm
formation, there was little evidence of this pressure acting over the
entire set of measured genes. Our finding that different genes are
preferentially targeted through different mechanisms in HNSCC
could reflect dramatic differences in the timing of these events (e.g.
one type of somatic changes predominating early in clonal
evolution with the other becoming dominant later in clonal
evolution). Alternatively, it is possible that other simultaneous
genetic events obviated the need for epigenetic modifications (e.g.
copy number-activating mutations common in other cancers [49])
or that sequence context (e.g. proximity to fragile sites or the CpG
Figure 3. Log significance plots for mean alteration difference in array genes. Gene regions were compared to their expected value
(normal tissue betas for methylation and copy number=2 for CNA) and t-tests were performed. Negative log-transformed p-values (generated by
tumor/normal t-tests) are shown on the y-axes and the indicated mean alterations are displayed in the x-dimension. The space above the dotted line
represents a significance level of p,0.05. A) Promoter-associated methylation alterations (663 genes) and copy number-altered genes (n=15,790) are
shown and B) separated by overall methylation class structure (Left Class n=10, Right Class n=9) as defined by grouping the methylation classes
based on the original RPMM dendrogram splitting in [20].
doi:10.1371/journal.pone.0009651.g003
Figure 4. Copy number plots by RPMM class. Copy number data
for 19 tumors are coordinately arranged by chromosome and grouped
together according to RPMM-modeled methylation classes. The total
number of methylation classes is reduced from the original six [20] to
five in this study because membership in Class 2 methylation profile is
not represented in the subset of 19 tumors investigated.
doi:10.1371/journal.pone.0009651.g004
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exposure to select the order and the type (epigenetic or genetic)
of alteration that inactivates genes. At the same, our stratified
analysis of the two main biological methylation subgroups revealed
that the events leading to abnormal copy number and CpG
methylation are fundamentally different in each group, suggestive
of an overall collateral relationship.
In sum, epigenetic profiles in HNSCC are significantly
associated with the extent of CNA, but this global relationship is
not widely reflected at the local level. Furthermore, the molecular
targets of each are dissimilar. The precise mechanisms responsible
for gene inactivation are obscure but in the framework of
carcinogenic progression within Knudson’s two-hit model, our
data indicate that local, coordinate DNA methylation and copy
number alteration do not dominate the profile of changes in
primary HNSCC.
Materials and Methods
Study Population/Ethics. The study group were members of a case-
control population presenting at Boston-area hospitals from 2000–
2004, as previously described [50]. In short, samples from incident
cases of HNSCC were microscopically examined and histologi-
cally confirmed to have .75% tumor content by the study
pathologist. This study was conducted according to the principles
expressed in the Declaration of Helsinki. Selected patients were
enrolled upon providing written, informed consent. All protocols
and documentation were approved the Brown University
institutional review board administered through the Research
Protections Office (Protocol #0707992334). Clinical information
was collected and HPV16 status was assessed using short fragment
PCR to amplify a region of the L1 gene of HPV16, according to
previously published methods [51].Tumor specimens from all
head and neck sites (excluding glandular, nodal, and nasopharyn-
geal carcinomas) selected for CpG methylation analysis included
26 fresh-frozen samples and 42 formalin-fixed paraffin-embedded
(FFPE) archived pathology samples. From those 68 samples, 19
fresh-frozen tumors were selected for copy number analysis by
frequency matching to the larger methylation cohort on age,
gender, and stage. Matched peripheral blood was used for SNP-
probe normalization. Eleven fresh-frozen non-malignant speci-
mens from the oral cavity, pharynx, and larynx were procured
through the National Research Disease Interchange (NRDI).
DNA Extraction and Array-based Methylation Analysis. FFPE tumors
were sectioned and DNA was isolated, as previously published
[20]. DNA was extracted from fresh-frozen tissues and matched
peripheral blood samples using the QIAamp DNA mini kit
according to the manufacturer’s protocol (Qiagen, Valencia, CA).
For methylation assessment, sodium bisulfite modification of the
DNA was performed using the EZ DNA Methylation Kit (Zymo
Research, Orange, CA) with 1 mg of DNA, as described previously
[20]. Illumina GoldenGateH methylation bead arrays were used to
simultaneously interrogate 1505 CpG loci associated primarily
with promoter regions of 803 genes. Arrays were run at the
University of California- San Francisco Genomics Core Facility
according to the manufacturer’s protocol.
LINE-1 Methylation. Global DNA methylation was quantified for
11 of the 19 tumor samples with available substrate by
pyrosequencing following bisulfite-PCR, with primers and proto-
cols as described in [52]. Four CpG dinucleotides within the
human LINE-1 transposon consensus sequence 302–331 (Acces-
sion X58075) were analyzed using the PyroMark Q96 MD system.
DNA methylation at each locus was calculated by taking the
percent of methylated signal divided by the sum of the methylated
and unmethylated signals and reported as the mean over all four
CpGs. Pyrosequencing reactions were performed in triplicate and
bisulfite conversion efficiency was monitored using internal non-
CpG cytosine residues.
SNP Genotyping for Copy Number Status. Tumors were examined for
copy number alterations by hybridizing isolated tumor DNA to
the GeneChipH Human Mapping 500 K single-nucleotide poly-
morphism array (Affymetrix, Santa Clara, CA) following estab-
lished protocols according to the manufacturer at the Harvard
Partners Microarray Core Facility. Probe intensities at each locus
were determined in the Affymetrix GeneChip Operating Software
and genotypes calls were generated using the Genotyping Analysis
Software (Affymetrix). Probe signals were normalized to the
matched samples using Copy Number Analysis Tool v4.0.1 [53]
(Affymetrix) with the defaults for tuning parameters, Gaussian
smoothing, transition decay, and median scaling. Copy number
states were inferred by Hidden Markov Model analysis in the same
application.
Statistical Analysis. BeadStudio software from the array manu-
facturer Illumina (San Diego, CA) was used for methylation
dataset assembly. All array data points are represented by
fluorescent signals from both M (methylated) and U (unmethy-
lated) alleles, and methylation level is given by b=(max(M, 0))/
(|U|+|M|+100), the average methylation (b) value is derived from
the ,30 replicate methylation measurements and a Cy3/Cy5
methylated/unmethylated ratio. Subsequent analyses were carried
out in the R statistical software package (http://www.r-project.
org/). For visualization, hierarchical clustering was performed on
sample copy number data calls using a Hamming distance metric
and calculated by Ward’s minimum variance method. Copy
number clusters were dichotomized into low and high allelic
imbalance (Figure 1A); the difference in absolute mean LINE-1
methylation between the two groups was estimated and confidence
intervals were computed. Fisher’s exact test for small sample sizes
was used to test the degree of abnormal copy number (high/low
clustering) for association with the covariates stage (dichotomized
as I/II and III/IV), site, and presence of absence of HPV16 viral
integration, using a Monte Carlo simulation for site. A Wilcoxon
rank-sum test was used to test age as a continuous variable versus
degree of copy number variation. For visualization of methylation
data, tumors were ordered first by methylation classifications
developed in [20] by a recursively partitioned mixture model
(RPMM), as described in Houseman et al. [31]. Finally, the
terminal nodes were obtained by hierarchically clustering
methylation b values using Ward’s method with a Euclidean
distance metric.
Although the 19 tumor samples were the primary focus of this
investigation, we used the six classes obtained from the RPMM-
clustering on 68 tumors, described in [20], because we anticipated
better precision in capturing the true biological inferences with the
larger sample size. The relationship between DNA copy number
and methylation class membership was tested using the mean
value of |CNS-2|, where CNS is the copy number state of each of
500,446 loci. A permutation test with 10 k iterations using the
Kruskal-Wallis test statistic was performed. Locus-specific rela-
tionships between copy number and methylation were examined
graphically in a chromosome-specific manner. Analyses were
restricted to autosomal chromosomes. We investigated the local
relationship between methylation and CNA at 1413 loci by
calculating the Pearson product-moment correlation coefficients.
Note that the discrete nature of the Hidden Markov Model
motivates the use of the Pearson, rather than Spearman,
coefficient. GoldenGate CpG loci were matched to Affymetrix
SNPs in the manner described in [32]. In short, each locus was
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NCBI36 coordinate (typically within 1 kb). P-values were
calculated via permutation test (5 k permutations). To correct
for multiple comparisons, q-values were computed by the qvalue
package in R. To assess correlation at the gene (rather than locus)
level, CpGs were matched to genes by chromosomal position, and
assigned promoter status if they were upstream of the TSS.
Methylation at promoter CpGs were averaged together by gene.
Similarly, copy number calls were averaged together for all SNPs
associated with a gene. To investigate the molecular processes
individually by locus, two-sided, two-sample t-tests assuming
unequal variance were used to compare methylation between
the 19 tumors and 11 non-diseased tissues. For copy number, a
one-sample t-test was used, with the normal copy number call
assumed to be 2. Mean alteration differences were considered
statistically significant where q,0.05.
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